Stress has long been suspected as having major effects on metabolic activity. The effects of stress on glucose metabolism are mediated by a variety of "counter-regulatory" hormones that are released in response to stress and that result in elevated blood glucose levels and decreased insulin action. This energy mobilizing effect is of adaptive importance in a healthy organism. However, in diabetes, because of a relative or absolute lack of insulin, stress-induced increases in blood glucose cannot be adequately metabolized. Thus, stress is a potential contributor to chronic hyperglycemia in diabetes, although its exact role is unclear. Although there is some suggestion from retrospective human studies that stress can precipitate type I diabetes, animal studies are contradictory with different stressors either having facilatory or inhibitory effects upon the development of the disease. Human investigations in patients with established diabetes are equally confusing with some showing that stress can stimulate hyperglycemia, hypoglycemia or have no effect at all on glycemic status. There is more consistent evidence supporting the role of stress in animal models of type II diabetes. However, human studies on the role of stress on the course of established type II diabetes are few. Intervention studies suggest that behavioral or pharmacologic intervention to manage stress may contribute significantly to diabetes treatment, but more long-term research is needed. It is concluded that further research is needed to establish the importance of behavioral factors in the etiology and management of diabetes, and several areas of methodologic improvement are suggested. Key words: Diabetes mellitus, stress, hyperglycemia, hypoglycemia, catecholamines, sympathetic nervous system.
Diabetes mellitus is a group of disorders that share a common defect in the control of carbohydrate metabolism. The term diabetes mellitus refers to the sweet tasting urine of patients with the disease, a symptom first described by Areteus over 2000 years ago. By the end of the 19th century, physicians were beginning to refer to at least two types of diabetes mellitus. William Osier (1) described one type of diabetes, usually appearing in youth and always fatal, and another, which he termed diabetes of obesity which was treatable by diet. These two basic distinctions are still used today and the conditions are referred to as type I or insulin dependent diabetes, and type II or noninsulin dependent diabetes, respectively. It is estimated that over 14 million Americans have diabetes with 13 million cases of type II diabetes and between 500,000 to 1 million cases of type I diabetes (2). Because type II diabetes is associated with aging, this form of the disease is becoming more and more prevalent. Approximately 15% of all American adults over 65 are thought to have the disease (2).
Type I diabetes is now known to be caused by an autoimmune process in which the beta, or insulinproducing cells in the Islets of Langerhans, are targeted and destroyed by the body's own immune system (3) . Without insulin, glucose cannot be utilized by most somatic tissue (the brain is one organ that does not require insulin to metabolize glucose) and protein and fat are metabolized instead. Fat metabolism produces large amounts of ketoacids, which if left untreated can lead to death. The tendency to develop this immune response is inherited, but as only 50% of identical twins are concordant for type I diabetes, other factors such as environment must play a role (3) . Type II diabetes is probably a heterogenous group of conditions in which insulin secretion is not absolutely compromised. In some patients, insulin secretion can be greater than normal, the metabolic defect being that the body is insulin resistant and does not respond to its own insulin. In other type II patients, insulin resistance may be minimal, the primary problem being that the pancreas does not secrete adequate quantities of insulin in response to glucose stimulation (4) . Both varieties of type II diabetes can usually be treated by a controlled diet, weight reduction (which reduces insulin resistance), and/or oral medications that stimulate additional insulin secretion and reduce insulin resistance. However, insulin therapy can be used for these patients as well in certain cases.
Conventional theories of the pathophysiology of type II diabetes suggest that the disease is due to either a primary defect in the beta cell, making it less responsive to glucose stimulation, or to the severe insulin resistance that eventually exhausts beta cell function (5). However, attempts to find a defect in the beta cell or a mechanism for insulin resistance in somatic cells have been frustrating. Examination of genes that code for insulin production or insulin receptor expression have failed to find defects in these functions (6) . Over the last 10 years, there has been speculation that the autonomic nervous system is involved in the pathophysiology of type II diabetes (7) (8) (9) (10) (11) . This possibility was foreseen by Claude Bernard who found that hyperglycemia could be produced in normal rabbits by lesioning the area of the hypothalamus. More recently, several researchers have shown that hyperglycemia can be produced by chemical stimulation of the brain with morphine and by a variety of endogenous neuropeptides and can be abolished by bilateral adrenalectomy (9, 12) . Hyperglycemia has also been found to occur from a slow intravenous infusion of epinephrine (13) and from the type of stress that results in prolonged sympathetic discharge (14). Autonomic activity leading to metabolic decompensation could be stimulated by stress (11, 15) , or by the effects of dietary fat and carbohydrate on sympathetic outflow (e.g., 16, 17) .
With proper medical treatment, the consequences of severe hyperglycemia can be avoided and life can be prolonged. However, moderately elevated blood glucose levels over a long period may be related to the eventual appearance of the "long-term" complications of diabetes. It is widely believed that hyperglycemia is the key factor in the development of neuropathy, nephropathy, and probably retinopathy (5). It is associated with atherosclerotic disease as well. Furthermore, intensive treatment regimes designed to reduce hyperglycemia have had favorable effects on risk factors such as lipid abnormalities which may be important in the development of atherosclerosis (18) . More recently, investigators have been studying the relationship between hypertension and diabetes. Between 30 to 50% of patients with newly diagnosed type II diabetes have hypertension (19) .
As we have previously noted, both type I and type II diabetes provide excellent disease paradigms within which the role of psychosocial stimuli can be evaluated (20, 21) . Of all chronic diseases, perhaps none demands more compliance on the part of the patient than diabetes, and few diseases impact the family of the patient as significantly. One of the major questions regarding the role of behavior in diabetes mellitus is how stress may effect the pathophysiology of the disease. In the following pages, we will attempt to provide a current overview of the research on how stress may contribute to the pathophysiology of type I and type II diabetes as well as a review of the studies that have assessed the utility of behavioral and pharmacologic anxiolytic therapy in the treatment of these diseases. Our purpose is 3-fold. First, we educate the reader as to the status of our knowledge in this area. Second, we hope to constructively point out the weaknesses in previous studies that need to be addressed in the future. Above all, we hope to stimulate interest among those involved in psychosomatic research in what we feel is a most fascinating problem.
EFFECTS OF STRESS ON GLUCOSE METABOLISM
Stress hormones are referred to as "counter-regulatory" by endocrinologists because they generally have a hyperglycemic effect. These effects are summarized in Table 1 . Adrenergic stimulation of pancreatic islet cells can lead to either facilitation or inhibition of insulin secretion. Beta adrenergic stimulation is facilitory to insulin output while alpha-2 adrenergic stimulation is inhibitory. Beta adrenergic stimulation also stimulates glucagon release from the pancreatic alpha cells. Glucagon, in turn, stimulates glucose production in the liver. Beta adrenergic stimulation also promotes the conversion of glycogen to glucose in the liver as well as fat to free fatty acids in adipose tissue (22) (23) (24) . Branches of the parasympathetic vagus nerve innervate the pancreatic islets as well, and stimulation of the right vagus causes increased insulin secretion (23) . In this fashion, both sympathetic and parasympathetic innervation of the pancreas modulate the normal regulation of carbohydrate metabolism.
Stressful stimuli can also result in elevated blood glucose levels via several different hypothalamicpituitary pathways. Cortisol causes enhanced glucose production by the liver and diminished cellular glucose uptake. Bjorntorp (15) has hypothesized that this mechanism may lead to both central obesity and a predisposition to diabetes if individuals are exposed to chronic stress. Stress-induced release of growth hormone and beta-endorphin can also decrease glucose uptake, suppress insulin secretion, and elevate glucose levels (9) . There are also vagal afferents form the liver to the CNS as well as receptors in the brain for numerous peptide hormones originally found in the gut (25) . The adaptive benefit of the mechanism of stress-induced energy mobilization in healthy individuals is obvious, but in diabetic individuals, where glucose metabolism is compromised, these stress effects can be problematic.
STRESS AND TYPE I DIABETES
Because diabetes is really a group of very different diseases, it is important to examine the question of how stress may affect diabetes onset and control in relation to specific diagnostic categories. Accordingly, we will review studies on type I and type II diabetes separately. Because animal models of both types of diabetes have been studied, and stress effects have been examined in human clinical studies, we will review both types of studies for each type of diabetes.
Animal Models Animal research has provided evidence to suggest that stress effects the "onset" of diabetes. Half a century ago, Cannon (26) described stress-induced hyperglycemia in normal cats. In this early investigation 12 cats were confined in a holder, for varying lengths of time, which were dependent on the animals' reaction to this novel situation. The cats were given a large quantity of water by stomach tube and urine was drained promptly. In all of the cases, sugar was absent from the urine before the animal became excited, conversely, the stress intervention invariably resulted in glycosuria. Cannon (26) observed an apparent relationship between the animals' emotional state and the onset of the hyperglycemia. Specifically, those animals that seemed to be frightened or enraged developed glycosuria more quickly than animals that responded to the confinement in a calm manner. Although Cannon described stressinduced hyperglycemia in normal animals, there have only been a limited number of studies on the effects of stress on diabetic animals.
Surgically partially pancreatectomized animals have been shown to develop either transient or permanent diabetes following restraint stress (27) . Although these animals did not develop diabetes spontaneously, restraint stress produced transient or permanent diabetes in a significant percentage of pancreatectomized animals. Some animals who were not surgically altered became hyperglycemic following the stressor, but none developed diabetes. More recently, chemical pancreatectomy with B-cell cytotoxins such as alloxan and streptozotocin has been used instead of surgical procedures. Through control of the dosage, partial or complete destruction of pancreatic beta cell mass can be produced, mimicking the clinical picture of type II and type I diabetes, respectively.
One group of investigators (28) reported that lightshock stimulation could inhibit the development of streptozotocin-induced diabetes in young mice receiving a single dose of streptozotocin, but the mechanism of this effect was not defined. Because the administration of exogenous steroids can inhibit the development of another streptozotocin-induced model of diabetes (29) , it is possible that the protective effect of stress on the development of diabetes observed in animals treated with a single dose of streptozotocin may have been mediated through the adrenal corticotropic effects.
There is also a genetic model for type I diabetes, the diabetes-prone BB Wistar rat (30) . These animals are prone to spontaneously develop an autoimmune insulitis resulting in diabetes by the time they are 5 months old. Carter et al. (31) found that a combination of behavioral stressors such as restraint and crowding could lower the age of onset of diabetes as well as to increase the percentage of animals who ultimately developed diabetes. However, BB rats possess other endocrine and immune abnormalities that limit the generalizability of these studies to humans.
Bellush and Rowland (32) found that rats made diabetic with streptozotocin had reliably higher norepinephrine than controls both before and after footshock. Epinephrine was found to increase in diabetic animals after stress and decrease in controls. The authors conclude that the elevated norepinephrine levels in the diabetic rats suggests increased sympathetic activity in those animals. Lee, Konorska, and McGarty (33) found similar results in a subgroup of animals they studied. These studies highlight the complex nature of the relationship between envi-ronmental manipulations and diabetes in animals who are susceptible to the disease.
Human Studies
Role of stress in the onset of type 1 diabetes. Stress has been suspected to play a role in the onset of Type I diabetes in humans as well. Fifty percent of identical twins are concordant for type I diabetes. Because twins usually show evidence of autoimmune abnormalities, it has therefore been postulated that some environmental stimulus is necessary for the overt expression of the disease. Stress may therefore affect the onset of type I diabetes by triggering this autoimmune abnormality. However, conclusive evidence for this mechanism is lacking. Studies have shown that people with diabetes are more likely to suffer a major family loss before diagnosis (34) (35) (36) . However, these studies tend to be poorly controlled and/or they rely on recall of specific life events. One of the better studies that did compare diabetic patients with similar age nondiabetic siblings and a matched neighborhood control group found that diabetic patients have significantly more severe life events within the 3 years before diagnosis than either control group (34) .
Stress and gJucose control in type I diabetes. The investigation of the effects of psychological stress on glucose metabolism in diabetic patients was first undertaken by Hinkle and his co-workers (37) (38) (39) . Their studies demonstrated increases in blood glucose and ketones following stressful psychiatric interviews in diabetic patients. However, their work was not tightly controlled and is difficult to interpret. Vandenbergh, Sussman, and Titus (40) examined the impact of hypnotically induced emotion on predominantly type I subjects in a controlled fashion. Coincident with nonsignificant increases in plasma-free fatty acids, they observed blood glucose decreases. These findings were replicated in a subsequent study (41) . However, these investigators did not fully document whether or not their subjects had endogenous insulin reserves.
Not all studies have demonstrated that laboratory stress leads to blood glucose changes in type I diabetes patients. In one study, patients with good glycemic control were compared with individuals in an acute state of insulin insufficiency. Following mental arithmetic and public speaking stressors, neither group showed significant changes in blood glucose levels (42) . Since artificially induced insulin deficiency may not be comparable to chronic poor glycemic control, Gilbert et al. (43) compared children with good glycemic control with those who had a history of poor control as measured by glycosolated hemoglobin. Neither group showed a significant change in blood glucose after a public speaking stressor although the poorly controlled patients had higher poststress urine glucose levels.
Some studies have raised the possibility of idiosyncratic changes in blood glucose after laboratory stressors. Bradley (44) found that noise stress increased blood glucose in initially hyperglycemic diabetic subjects and decreased blood glucose in initially hypoglycemic diabetic subjects, although Carter et al. (45) found that mental arithmetic can produce both increases or decreases in blood glucose in patients with type I diabetes and that the direction of blood glucose change is idiosyncratic. This group later replicated this finding and demonstrated that about 50% of patients had clinically and statistically significant increases or decreases in blood glucose following an active stressor, mental arithmetic (46) . There were no significant overall changes and no individual data was reported for the passive stressor, viewing a gory film. A recent study has suggested that these idiosyncratic differences in glycemic response to stress may be due to differential changes in injection site blood flow in response to stress (47) . These changes are thought to be mediated by catecholamine activity on local blood flow.
Personality variables have been related to glycemic responsivity to stress in diabetic patients. Stabler et al. (48) found that type A children showed elevated blood glucose levels after playing a stressful videogame while Type B children showed decreased blood glucose levels. Type A children had higher glycohemoglobin levels than Type B children. Glycohemoglobin is a glycosylated protein that can be used as an index of average blood glucose. A subsequent study failed to replicate the glycohemoglobin differences between types A and B children although glucose reactivity to stress was not assessed (49) .
Several physical stressors such as illness or trauma have been shown to cause hyperglycemia and eventual ketoacidosis in patients with type I diabetes (50) . McLesky, Lewis, and Woodruff (51) found a clear hyperglycemic response in patients with both types I and II diabetes during a surgical stress. Other types of negative life events have also been shown to have an influence on diabetic control. Chase and Jackson (52) found that in children, life stress is correlated with both glycosolated hemoglobin and blood glucose suggesting that it has an impact on both long-and short-term indices of glycemic control. Brand, Johnson, and Johnson (53) on the other hand found life stress to only be correlated with urinary ketone levels in boys. These studies used different measures of life stress and neither investigated whether the findings suggest a direct effect of stress on glycemic control or an indirect effect based on poorer compliance. Using a prospective, in vivo design, Halford, Cuddihy and Mortimer (54) demonstrated that life stress predicted blood glucose levels independent of diet in 50% of patients. There were no significant differences in blood glucose levels between patients who did exhibit a relationship between stress and blood glucose and those who did not.
In summary, some of the studies investigating the impact of psychological stress on blood glucose in human diabetes report that stress has a general hyper-or hypoglycemic effect, although others find that the response is idiosyncratic, with some patients showing increases and others decreases in blood glucose in response to stressful stimuli. Some data exist to suggest that these individual differences are related to personality variables.
Another way to study the effects of stress in type I diabetes is to model the effects of stress on metabolism by administering stress hormones and measuring the metabolic effects that follow. The advantage of these procedures is that they are easy to define operationally and results from them tend to be more replicable than those involving behavioral stress. Consequently, it is not surprising that the data on the role of stress hormones (catecholamines, cortisol, growth hormone), in the development of hyperglycemia and ketosis in type I diabetes appears to be more consistent than that from stress studies. However, because stress orchestrates a complex interaction of many neuroendocrine variables simultaneously, the relevance of single neuroendocrine agonist challenge studies to diabetes must be interpreted with caution. Insulin-dependent diabetic children have been shown to demonstrate elevated blood glucose and more rapid ketone release following epinephrine infusion compared with normal children (55) . Small, intravenous doses of epinephrine were shown by Ferngvist, Gunnarsson and Linde (56) to decrease absorption of insulin in both healthy and diabetic subjects, even though subcutaneous blood flow remained stable or increased. At levels of epinephrine infusions intended to mimic moderate physical stress, insulin absorption may be retarded by as much as 50%. Sherwin et al. (57) examined the effects on blood glucose of infusions of epinephrine, glucagon and cortisol both alone and in combination in normal and type I diabetic subjects. Although the diabetic subjects received insulin infusions for several hours before the injection of the hormones, the elevation of blood glucose was significantly greater in the diabetic group compared to normal controls. This increase was sustained in the diabetic patients over a 5-hour period, but lasted less than 2 hours in the controls. Cortisol infusions produced hyperglycemia in both groups with increases in hepatic glucose production observed only in diabetic patients.
BEHAVIORAL AND PHARMACOLOGIC ANXIOLYTIC THERAPY IN TYPE I DIABETES
Despite the lack of conclusive evidence of a relationship between stress and blood glucose, there have been several attempts to control stress responses in patients with type I diabetes. Therapeutic approaches aimed at reducing the stress response and its metabolic effects in diabetic patients have included intensive family therapy (58) , and longterm beta blockade (59) . However, psychotherapeutic approaches are costly, and long-term beta blockade may increase the risk of unheralded hypoglycemia and interfere with the recovery from a hypoglycemic event in patients with type I diabetes. Relaxation techniques have offered a potential alternative. Relaxation has been used in the treatment of a variety of autonomically mediated illnesses (60) . Relaxation seems to decrease adrenocortical activity (61, 62) as well as circulating levels of catecholamines (63, 64) . Thus, relaxation therapy might serve to moderate some of the negative effects of the stress response on metabolic control in some diabetes patients. Moreover, relaxation is not associated with the undue adverse effects caused by adrenergic blockade.
There is a growing literature reporting the results of experimental applications of relaxation training in type I diabetes. Fowler, Budzynski, and Vandenbergh (65) reported that intensive relaxation training and EMG biofeedback lowered the insulin requirements and reduced the frequency of ketoacidosis in one patient with type I diabetes but they failed to provide outcome data. Seeburg and DeBoer (66) reported the treatment of a similar case of type I diabetes. Although relaxation training appeared to produce a significant reduction in the patient's insulin requirement, the patient began to experience frequent hypoglycemia and training had to be discontinued. Rosenbaum (67) also reported some success with a combined program of EMG biofeedback and relaxation training with four patients with type I diabetes and two with type II diabetes who were being treated with insulin.
Although these case reports provide suggestive evidence for the utility of relaxation training in the control of plasma glucose in diabetes, they have been relatively uncontrolled and the patient populations reported on have been poorly defined. There have been three recent reports of the application of relaxation training to patients with clearly documented type I diabetes. Landis et al. (68) trained six patients with type I diabetes who were being closely followed and intensively treated. Although absolute glucose levels, glycohemoglobin, and insulin requirements did not change significantly after training, patients did appear to experience an improvement in plasma glucose control as measured by the daily range in blood glucose levels divided by the daily insulin dose. Bradley et al. (69), compared conventional insulin treatment, insulin treatment with a continuous subcutaneous insulin infusion, conventional insulin treatment plus relaxation training, and conventional treatment plus biofeedback-assisted relaxation training. No differences among the four treatment groups were found on daily measures of blood glucose or glycohemoglobin, although individual differences within groups were considerable.
Feinglos, Hastedt, and Surwit (70) investigated whether a relaxation program would affect glycemic control in 20 patients with type I diabetes who reported stress-induced elevations of blood glucose. Patients in the treatment group were given five biofeedback sessions and instructions to practice twice daily during a 1-week hospitalization period and at home after discharge. Relaxation did not significantly improve glucose tolerance in treated patients compared to an attention control group. Furthermore, there were no differences between treatment and control groups in mean daily blood glucose, required insulin dose, or other measures of chronic control.
SUMMARY: STRESS AND TYPE I DIABETES
The weight of the evidence from animal and human investigations argues persuasively for a role for stress in the course of type I diabetes. There are, however, inconsistencies in the literature that may be attributable to methodological problems. First, animal models that produce artificially induced diabetes, create pathophysiologic conditions that are not completely analogous to human type I diabetes. For instance, pancreatectomized animals undergo potentially stressful procedures that differ from the more gradual onset of type I diabetes in humans (71) . The stress of the sudden onset of the condition in these animal models may lead to changes in catecholamines independent of the effects of experimental stressors on the condition itself (33) . Second, in many of these studies, animals often have chronic hyperglycemia which is not being controlled by insulin, yielding results that may not be generalizable to humans with type I diabetes in which reasonable glycemic control is maintained with insulin.
Although the human literature contains some contradictory findings, there are several explanations for apparently disparate results in studies on the effects of stress in human type I diabetes. First, the term "stress" is itself a cause of confusion. Stress has been used to describe a variety of both experimental stimuli and responses. For instance, noise can be viewed as a stressful stimulus because it can produce an autonomic response in a passive subject. However, mental arithmetic is a behavior in response to the stimulus of experimental instructions and thus not a stimulus itself. The presentation of arithmetic problems does not evoke a response without the subject performing the arithmetic and therefore mental arithmetic is best viewed as a response that is accompanied by an autonomic reaction. In the experimental studies just cited, few investigators used the same stress paradigm. In the naturalistic, correlational studies, the definition of stressful life events varied as well. Hence, the disparity of results is not surprising.
A second problem with human studies of stress in type I diabetes is that baseline measures are often absent or inadequate, and there are frequently no checks on the effectiveness of the stress manipulation. Some of the procedures used to control subjects' blood glucose levels at baseline, such as overnight fasting, may be stressful to the subjects (72) . Furthermore, many of the above studies did not carefully describe the nature of their subjects' diabetes. The effects of a given environmental stimulus on a patient with some endogenous insulin could be quite different than if applied to a patient without endogenous insulin.
Finally, disruptions in autonomic nervous system activity, due to diabetic neuropathy, can lead to decreased sympathetic responses in diabetic patients (73) . In patients with known autonomic neuropathy, mental arithmetic stress does not produce the typical changes in skin temperature and heart rate that is found in patients without neuropathy and nondiabetic controls (74) . Because these sympathetic nervous system defects are very common in diabetes, Cryer (73) has argued that increased sympathetic nervous system activity is not likely to be responsible for hyperglycemia in type I diabetes. Differences in autonomic status among diabetic subjects may account for the different stress effects found in various studies, and may also explain why exogenously administered stress hormones produce more reliable hyperglycemic effects. Many of these difficulties are bypassed in studies in which stress is modeled by the infusion of "stress hormones" and results from these studies have been more consistent.
Although stress may affect glucose control in type I diabetes, it is not yet clear that these effects can be attenuated with behavioral intervention. Most of the reports of stress-management interventions have been uncontrolled and have employed few subjects. Controlled studies have failed to find significant effects. Individual differences, found to be important in the effects of stress on blood glucose levels, have not been investigated. The role of stress-reduction therapies in the treatment of type I diabetes remains to be elucidated.
STRESS AND TYPE II DIABETES

Animal Models
Role of stress in the onset of type II diabetes. Increased glycemic reactivity to stress and stress hormones is characteristic of several animal models of type II diabetes. An early observation of stress-induced hyperglycemia in an animal model of spontaneously occurring type II diabetes was made during metabolic studies of the sand rat (psammomys obesus). The sand rat is a North African rodent that develops diabetes when fed laboratory chow (instead of their native diet of succulent plants) and allowed to become obese (75). Mikat et al. (76) maintained sand rats on a low calorie, low carbohydrate diet of vegetables, and saline so that they remained euglycemic. Glucose or saline was then administered to rats either through an esophageal tube or intraperitoneally by injection. Similar procedures were carried out on a group of Sprague-Dawley rats. Sand rats experiencing esophageal intubation showed abnormal glucose tolerance which would be considered typical of diabetes. In contrast, in the Sprague-Dawley rats intubation did not alter normal glucose tolerance values. Thus, it seems that the stress of intubation precipitates glucose intolerance even in lean, euglycemic sand rats genetically predisposed towards developing diabetes.
Surwit, Feinglos, and colleagues have studied the effects of stress on hyperglycemia in another animal model of type II diabetes, the genetically obese mouse (C57BL/6J, ob/ob). This animal is characterized by a syndrome of obesity, hyperinsulinemia, insulin resistance, hyperglycemia, and glucose intolerance (75) . However, there has been some controversy over the degree to which the obese mouse is hyperglycemic. Different laboratories have reported varying "basal" plasma glucose levels ranging from 130 mg/dl to over 300 mg/dl (77) (78) (79) . In one study (80) blood samples were drawn from obese and lean mice after either a rest period or exposure to stress. Stress consisted of restraint in a wire-mesh cage for 60 minutes punctuated by a 5-minute period of shaking. Both lean and obese animals had an increase in plasma glucose levels produced by the stress. This effect was significantly greater in the obese animals than in their lean, nondiabetic littermates. In a later study, stress hyperglycemia was easily classically conditioned in C57BL/6J ob/ob mice, but not in a nondiabetic control strain (81) . Thus, the expression of hyperglycemia in this genetic model of type II diabetes can be seen to be dependent upon exposure to stressful stimuli. To study the mechanism by which stress seems to dysregulate glucose metabolism in obese mice, Surwit et al. (80) administered epinephrine to lean and obese animals. The results indicated that the effects of epinephrine were analogous to those of stress. That is, epinephrine produced an increase in plasma glucose in all animals with obese mice showing a greater response than their lean littermates. Likewise, epinephrine decreased plasma insulin only in obese mice. In a follow-up study (82) , epinephrine administration resulted in a dose-related increase in plasma glucose in lean animals in the dose range from 1 to 5 ^ig/10 g body weight, while plasma glucose responses were maximal at the lowest dose of epinephrine tested in the obese mice, suggesting that the dose response relationship is altered in obese animals. Furthermore, phentolamine, an alpha adrenergic antagonist, produced a greater increase in plasma insulin in ob/ob mice than the lean littermates, suggesting that this increased sensitivity to catecholamines may be largely alpha adrenergic. Altered peripheral responses to sympathetic stimuli appear to be important in the exaggerated glycemic responses of ob/ob mice to stress and may be an etiologic factor in the development of diabetes in these animals. Exaggerated sensitivity to alpha adrenergic stimulation has also been shown to be characteristic of the KK mouse, another animal model of type II diabetes (83) .
Most recently, Surwit and colleagues (84) have shown that altered adrenergic sensitivity might be a biologic marker for the development of type II diabetes in the background strain for the ob/ob mutation. These investigators observed that lean, nondiabetic C57BL/6J mice also show exaggerated glucose response to epinephrine when compared to several other nondiabetic strains. When placed on a high-fat, high-simple carbohydrate "junk food" diet, these mice develop type II diabetes and obesity as well as hypertension (85) . This has led this investigative team to speculate that altered sensitivity to adrenergic stimulation in the pancreas, liver, and possibly other sites as well may be related to the pathophysiology of type II diabetes (84) and hypertension (85) .
Human Studies
Role of stress in the onset of type II diabetes in humans. Despite numerous anecdotal reports of stress preceding the onset of type II diabetes, there are no data to argue for or against the importance of stress in the development of this disease in humans. However, several recent studies have suggested that individuals "at-risk" for type II diabetes may have some of the same autonomic nervous system abnormalities that have been identified in animal models. Pima Indian Native Americans are at extraordinaryly high risk for developing type II diabetes; approximately 60% of Pima Indian Native Americans eventually develop type II diabetes in adulthood, compared with 5% of the white population. Surwit et al. (86) have shown that young, euglycemic Pima Indians showed a disturbed glycemic response to behavioral stress compared with white. Pima Indians and whites were given a mixed meal that was followed 2 hours later by a 10-minute mental arithmetic stressor. Although all subjects showed normal glucose tolerance in response to the meal, 10 of 13 Pima Indians showed a hyperglycemic response to a mental arithmetic stressor although seven of eight white controls do not. This suggests that Pima Indians who are "at-risk" for type II diabetes may have exaggerated sensitivity to adrenergic stimulation. This conclusion was supported by another recent study in which sympathetic nervous system activity in young, nondiabetic Pima and white controls (87) was directly measured. Pima Indians showed significantly decreased sympathetic nerve activity to muscle compared with white controls that is consistent with increased adrenergic receptor sensitivity in the periphery. Thus, there is some evidence of a preexisting autonomic nervous system defect that could allow stress to play a role in mediating the onset of the disease.
Relationship Between Stress and Glycemic Control in Type II Diabetes Although there have been no studies of the role of stress on the onset of type II diabetes in humans, a modest literature on the effects of stress on control of type II diabetes has accumulated over the last 15 years. Grant et al. (88) looked at the role of stress in terms of the relationship between actual life events and fluctuations in the course of diabetes mellitus. Subjects included 15 patients with "juvenile onset" diabetes and 22 adult-onset diabetes patients. Their results suggested a relationship between life events, particularly those of a negative nature, and changes in diabetic symptomatology. However, direct metabolic effects may have been confounded with stressrelated changes in adherence to the diabetic regimen.
McClesky et al. (50) also investigated the effect of a physical stressor (surgery and anesthesia) on glucose and glucagon levels in both normal and diabetic patients. The subjects included nondiabetic patients, those with type I diabetes, and individuals with type II diabetes who were undergoing elective surgery. Serum glucagon and glucose levels were repeatedly sampled during the pre-, intra-, and postoperative periods. Throughout the time sampling period, the diabetic patients showed a clear hyperglycemic response to the surgical stress. Naliboff, Cohen, and Sowers (89) studied the effects of postural, hand grip, and mental arithmetic stressors in a sample of eight type II patients and eight controls. Although both physical and mental arithmetic stressors produced reliable elevations in catecholamines, glucose and other metabolic parameters failed to change in either group. However, some of the diabetic subjects seemed to have autonomic neuropathy that may have blunted metabolic responses to stress. Finally, Goetsch et al. (90) , did find acute hyperglycemic effects of mental arithmetic in six type II patients, but they did not measure other neuroendocrine parameters and no control group was used.
Although the mechanism of this stress responsivity in diabetic patients has not been directly studied, there is evidence of altered adrenergic sensitivity and responsivity in patients with type II diabetes as well. Linde and Deckert (91) and Robertson, Halter, and Porte (92) observed that alpha-adrenergic blockade with phentolamine increased glucose-stimulated insulin secretion in patients with type II dia-betes. Thus, as in animal models of this disease, alpha-adrenergic stimulation may be having a greater effect on insulin release in diabetic patients than in normals. This conclusion is supported by clinical studies in which selective blockade of alpha-2 receptors increased both insulin secretion and glucose disposal rate following a mixed meal in patients with type II diabetes (93) . Finally, it has been reported that glyburide, one of the sulfonylurea oral agents used to treat type II diabetes, binds to alpha-2 receptors in the pancreas suggesting that one effect of this drug on insulin secretion may be due to antagonism of adrenergic activity (94) .
Behavioral and Pharmacologic Anxiolytic Therapy in Type II Diabetes The investigation of the effects of stressful stimulation upon diabetes control can also be approached by investigating the effects of relaxation techniques that have been designed to reduce or modify an individual's response to stressful environmental stimuli. The use of such techniques in the treatment of diabetes has a long history. Before the discovery of insulin, it was common to treat diabetes of obesity that probably corresponds to what we consider to be type II diabetes today, with rest and opiates (1). More recently, relaxation techniques have been applied to the treatment of type II diabetes.
As reported earlier, Rosenbaum (67) demonstrated some improvement in two patients with type II diabetes using a comprehensive stress management program. Lammers, Naliboff and Straatmeyer (95) used a multiple baseline single subject design to investigate specific effect of progressive muscle relaxation on blood glucose levels in four insulin requiring type II diabetes patients. Progressive muscle relaxation significantly lowered blood glucose levels in two of the four subjects.
Although these studies provide suggestive evidence for the utility of relaxation training in the control of plasma glucose in diabetes, they were relatively uncontrolled and the patient populations were not adequately defined. There has been one recent study of the controlled application of relaxation training to patients with clearly documented type II diabetes. Surwit and Feinglos (96, 97 ) studied the acute effects of relaxation training on glucose tolerance in a carefully defined population of patients with type II diabetes. Nine men and three women with type II diabetes in poor control, who were not using insulin, served as subjects. All patients were hospitalized for 9 days and diet, exercise, and other extraneous stimuli and behaviors where held constant. Half of the patients were assigned to receive instruction in a modified version of progressive relaxation supplemented by EMG biofeedback. Six control patients remained in the hospital under conditions identical to that of the treatment group except they did not receive relaxation training. Although fasting glucose improved for all subjects with hospitalization, glucose tolerance improved significantly in patients who had received relaxation training as compared with controls. The improvement in glucose tolerance was not accompanied by a change in insulin sensitivity, insulin secretion, or plasma glucagon. Plasma cortisol and catecholamines were measured immediately before the first and second glucose tolerance test. Subjects receiving relaxation also showed a decrease in plasma cortisol between the first and second glucose tolerance tests whereas control subjects showed an increase over the same period (97). Plasma catecholamines decreased in both groups from the first to the second test. However, differences in catecholamine levels between the groups were not significant.
Recently, Surwit et al. (98) reported the results of a larger study that attempted to see if a similar relaxation training program could add incrementally to intensive medical therapy in a sample of 38 patients with type II diabetes. All volunteers were assigned to a relaxation training and diabetes education or diabetes education-alone group. They were admitted to the hospital for an initial metabolic assessment and then given outpatient relaxation training for 8 weeks. Patients were then readmitted to the hospital. Assessment admissions were repeated at 24 and 48 weeks. Although training failed to significantly improve any measure of glycemic control (glucose tolerance, fasting glucose, or glycohemoglobin), there was much individual variability of metabolic response to relaxation training. Metabolic response to relaxation training was predicted by psychological variables as well as responses to pharmacologic challenges. Individuals who showed high trait anxiety and neuroticism scores, and who showed large glycemic responses to epinephrine showed greater improvements in glucose tolerance after relaxation training than patients who showed the opposite characteristics.
There is also evidence that anxiolytic pharmacotherapy can be used to attenuate the effects of stress on hyperglycemia in type II diabetes. Surwit et al. (99) gave lean and obese diabetic mice injections of either alprazolam, a triazolobenzodiazepine, or vehicle alone before exposure to restraint and shaking stress or to a no stress-control period. Blood samples were then drawn and subsequently analyzed for glucose, insulin, and corticosterone. The results indicated that during stress alprazolam significantly lowered plasma glucose in obese but not lean mice, and it also reduced plasma corticosterone more in obese mice than in lean mice. The implication from these findings is that benzodiazepines might have a role in the modification of stress hyperglycemia in type II diabetes. These investigators have recently shown that alprazolam will produce small but reliable improvements in glucose tolerance in a sample of patients with type II diabetes (98). Patients were given two glucose tolerance tests, one with no other medication and one after oral administration of 1 mg of alprazolam. Alprazolam significantly reduced incremental glucose area compared with that observed on the control day.
SUMMARY: EFFECTS OF STRESS ON TYPE II DIABETES
In general, studies exploring the effects of stress and stress reduction techniques in type II diabetes have been somewhat more consistent in finding positive results. Stress has been shown to affect glucose acutely and chronically. Numerous animal studies exist which suggest that stress can adversely affect glycemic control in this form of the disease. Furthermore, there is evidence from both animals and humans which suggests that individuals with type II diabetes have altered adrenergic sensitivity in the pancreas (and perhaps other sites as well) which could make them particularly sensitive to stressful environmental stimulation. But, while there is substantial data showing the importance of stress in understanding hyperglycemia in animal models of type II diabetes, there is no direct evidence that stress plays a clinically significant role in the expression or control of the human disease. Furthermore, although there are some studies that show that relaxation can attenuate hyperglycemia in patients, these effects are not dramatic and have only been demonstrated in small numbers of patients.
Human research on the role of stress in type II diabetes has been less impressive than animal studies. Human stress studies and stress reduction intervention trials are difficult to perform and most studies have only used a small number of subjects. As in the study of type I diabetes, methodological differences between studies make results difficult to compare from one study to the other. Finally, although the sympathetic nervous system may play a role in the etiology of type II diabetes, glucose toxicity can eventually destroy the insulin secretory capability of the pancreas in humans (100) and, as in type I diabetes, neuropathy that results from chronic hyperglycemia (73) may make stress and neural factors less important in established disease than it is in developing disease.
SUMMARY AND CONCLUSIONS
Speculation regarding the role of stress in the onset and course of diabetes has been ongoing for over 300 years. Although the early literature did not clearly distinguish type I from type II diabetes, later studies have been more careful to examine separately the effects of stress on these two, very different diseases. There is only limited evidence to support the notion that stress may impact the onset of type I diabetes. The literature on the effects of stress on the course of the disease in experimental models and in clinical diabetes is complicated. In animal models, the effects of stress seem to depend upon the type of stress and the particular model studied. Also, because animal models of type I diabetes are rarely treated with insulin, they are metabolically unstable. It is, therefore, not immediately apparent how relevant these studies are to clinical problems. Human studies are confusing with some studies showing hyperglycemic effects, some showing no effects and some showing idiosyncratic effects, with patients demonstrating either hyper or hypoglycemia in response to the same stressor. As in animal studies, metabolic stability is often a confounding variable in that the degree of blood glucose control in the subject sample varies from study to study. Furthermore, insulin treatment regimens often differ among subjects, both within and across studies adding a further confounding variable. The temporal relationship between insulin dosage, meals, and stress must be carefully controlled in order for the metabolic effects of a behavioral manipulation to be interpretable. A final variable confounding most of these clinical observations is autonomic neuropathy, which develops over time and which would compromise any sympathetic nervous system response to stress (73) . There are little data on effects of stress reduction therapies in type I diabetes, and those that exist are inconclusive. More data are needed before we can conclude much about the effects of stress on type I diabetes control or how these effects would best be treated.
Although the literature on the effects of stress on type II diabetes is no more extensive than that of type I, results of both human and animal studies Psychosomatic Medicine 55:380-393 (1993) have been somewhat more consistent. This may be, in part, because of the fact that glucose control is more stable in these patients, but other factors have also been proposed. Stress and stress hormones have been typically shown to have a hyperglycemic effect on individuals and, in contrast to type I diabetes, stress-induced hypoglycemia has not been reported. Furthermore, both animal and human studies provide evidence of autonomic nervous system abnormalities in the etiology of type II diabetes in which there is an exaggeration of sympathetic nervous system effects upon glucose metabolism. This has led to the development of several theoretical models in which the sympathoadrenal/cortical system play a central role in the development of the disease. Several groups of investigators have speculated that behavioral stimuli that excite the autonomic nervous system and adrenocortical system may impair insulin secretion and glucose utilization as the disease develops (15, 101) and evidence is emerging that suggests that prediabetic individuals may be acutely susceptible to this type of stimulation. However, as in type I diabetes, the clinical impact of stress in the course of the disease is still far from clear. Long-term evaluations of the effects of stress on diabetes control in large numbers of patients are needed before the importance of stress in the course of the disease is understood. Similarly, more wellcontrolled studies evaluating the efficacy of stressreducing behavioral or pharmacologic interventions as an adjunct to treatment of this disease are needed before the clinical importance of stress management in the treatment of either type I or type II diabetes can be established.
Future studies to assess the effects of stress on either type I or type II diabetes can be improved by attention to several problems common to past research. First, because of the diversity of stressful stimuli that have been used in the studies that make up the literature, it is difficult to generalize from one study to the next. This problem can be solved by some standardization of stress-induction paradigms analogous to what has taken place in cardiovascular research. The addition of neuroendocrine data to substantiate the effects of stress on counterregulatory hormone activity would also be helpful. Changes in catecholamine and cortisol levels, for instance, could be expected in subjects that have been adequately stressed. Evaluating the negative stress effects on glucose metabolism, without these neuroendocrine data, is presently not possible. The evaluation of stress-management interventions as a treatment for diabetes requires the use of appropriate nonspecific control conditions. Because it is well known that any intervention is likely to focus the patient's attention on adherence to the treatment regimen, relaxation, and biofeedback treatments need to be compared with nonspecific "attentionplacebo" conditions, not to "no intervention at all." Finally, previous data strongly suggests that glycemic response to stress, as well as to stress-management interventions, is likely an individual difference, related to measurable psychometric constructs. Future research aimed at susceptible individuals should be much more fruitful than previous studies using heterogeneous groups of unselected subjects. It is therefore likely that as the methodology of future studies improves, the importance of stress in our understanding of diabetes will come into sharper focus.
